Paxman AB Asset Resilience Ratio
Paxman AB asset resilience ratio. Paxman AB (PAX) has an Asset Resilience Ratio of -3.83% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Paxman AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Paxman AB (2020–2020)
Asset resilience ratio of Paxman AB from 2020 to 2020. This chart shows how Paxman AB's Asset Resilience Ratio has changed over time. Read Paxman AB (PAX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Paxman AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Paxman AB balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-6.38 Million | -3.83% |
| Total Liquid Assets | Skr-6.38 Million | -3.83% |
Asset Resilience Insights
- Limited Liquidity: Paxman AB maintains only -3.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Paxman AB Industry Peers by Asset Resilience Ratio
Compare Paxman AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Paxman AB Asset Resilience Ratio by Year (2020–2020)
Paxman AB asset resilience ratio by year from 2020 to 2020. The table below shows the annual Asset Resilience Ratio data for Paxman AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 7.45% | Skr5.74 Million ≈ $617.18K |
Skr77.01 Million ≈ $8.29 Million |
-- |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more